Epigenetic Activation of Cytochrome P450 1A2 Sensitizes Hepatocellular Carcinoma Cells to Sorafenib
Drug Metabolism and Disposition · 2024-06 · 52 (6) · 555-564
DOI: 10.1124/dmd.124.001665 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Metabolism and Disposition, 2024-06. Verfasst von Yi Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan, China (Y.Z., J.F., Y.M., …. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Sorafenib, Liver Neoplasms, Epigenesis, Genetic. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Cytochrome P450 1A2 (CYP1A2) is a known tumor suppressor in hepatocellular carcinoma (HCC), but its expression is repressed in HCC and the underlying mechanism is unclear. In this study, we investigated the epigenetic mechanisms of CYP1A2 repression and potential therapeutic implications. In HCC tumor tissues, the methylation rates of CYP1A2 CpG island (CGI) and DNA methyltransferase (DNMT) 3A protein levels were significantly higher, and there was a clear negative correlation between DNMT3A and CYP1A2 protein expression. Knockdown of DNMT3A by siRNA significantly increased CYP1A2 expression in HCC cells. Additionally, treating HCC cells with decitabine (DAC) resulted in a dose-dependent upregulation of CYP1A2 expression by reducing the methylation level of CYP1A2 CGI. Furthermore, we observed a decreased enrichment of H3K27Ac in the promoter region of CYP1A2 in HCC tissues. Treatment with the trichostatin A (TSA) restored CYP1A2 expression in HCC cells by increasing H3K27Ac levels in the CYP1A2 promoter region. Importantly, combination treatment of sorafenib with DAC or TSA resulted in a leftward shift of the dose-response curve, lower IC50 values, and reduced colony numbers in HCC cells. Our findings suggest that hypermethylation of the CGI at the promoter, mediated by the high expression of DNMT3A, and hypoacetylation of H3K27 in the CYP1A2 promoter region, leads to CYP1A2 repression in HCC. Epigenetic drugs DAC and TSA increase HCC cell sensitivity to sorafenib by restoring CYP1A2 expression. Our study provides new insights into the epigenetic regulation of CYP1A2 in HCC and highlights the potential of epigenetic drugs as a therapeutic approach for HCC. SIGNIFICANCE STATEMENT: This study marks the first exploration of the epigenetic mechanisms underlying cytochrome P450 (CYP) 1A2 suppression in hepatocellular carcinoma (HCC). Our findings reveal that heightened DNA methyltransferase expression induces hypermethylation of the CpG island at the promoter, coupled with diminished H3K27Ac levels, resulting in the repression of CYP1A2 in HCC. The use of epigenetic drugs such as decitabine and trichostatin A emerges as a novel therapeutic avenue, demonstrating their potential to restore CYP1A2 expression and enhance sorafenib sensitivity in HCC cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan, China (Y.Z., J.F., Y.M., R.Q., Y.M., G.J., H.Z.) and Zhengzhou Tobacco Research Institute of Ch…
Zitieren
APA
Zhang, Y., Feng, J., Mi, Y., Fan, W., Qin, R., Mei, Y., Jin, G., Mao, J., & Zhang, H. (2024). Epigenetic Activation of Cytochrome P450 1A2 Sensitizes Hepatocellular Carcinoma Cells to Sorafenib. Drug Metabolism and Disposition, 52(6), 555-564. https://doi.org/10.1124/dmd.124.001665
Vancouver
Zhang Y, Feng J, Mi Y, Fan W, Qin R, Mei Y, et al. Epigenetic Activation of Cytochrome P450 1A2 Sensitizes Hepatocellular Carcinoma Cells to Sorafenib. Drug Metabolism and Disposition. 2024;52(6):555-564. doi:10.1124/dmd.124.001665
BibTeX
@article{Zhang2024,
author = {Zhang, Yi and Feng, Jingyu and Mi, Yang and Fan, Wu and Qin, Runwen and Mei, Yingwu and Jin, Ge and Mao, Jian and Zhang, Haifeng},
title = {Epigenetic Activation of Cytochrome P450 1A2 Sensitizes Hepatocellular Carcinoma Cells to Sorafenib},
journal = {Drug Metabolism and Disposition},
year = {2024},
volume = {52},
number = {6},
pages = {555--564},
doi = {10.1124/dmd.124.001665}
}
EUVIMED